Q4 2025 Aytu Biopharma Inc Earnings Call Transcript
Key Points
- Aytu BioPharma Inc (AYTU) reported a slight increase in net revenue for fiscal year 2025, reaching $66.4 million compared to the previous year.
- The company achieved its third consecutive year of positive adjusted EBITDA, amounting to $9.2 million.
- Aytu BioPharma Inc (AYTU) is set to launch EXXUA, a novel treatment for major depressive disorder, which is expected to transform the company's market position.
- The company has successfully outsourced ADHD manufacturing to a US-based CMO, enhancing operational efficiency.
- Aytu BioPharma Inc (AYTU) has a strong cash position with $31 million in cash and cash equivalents as of June 30, 2025, supported by a successful public offering.
- Gross margin decreased to 69% in fiscal year 2025 from 75% the previous year, primarily due to increased cost of sales in ADHD inventory.
- The company reported a net loss of $13.6 million for the year, impacted by an $8.3 million impairment expense on the pediatric portfolio.
- There is uncertainty regarding the impact of Teva's potential entry into the market with a generic version of Adzenys.
- The ADHD portfolio experienced a slight decrease in net revenue, attributed to a decrease in the number of scripts written.
- Aytu BioPharma Inc (AYTU) faces challenges in maintaining market share in the highly genericized ADHD market.
Greetings. Welcome to the Aytu BioPharma to report fiscal 2025 full year and fourth quarter operational and financial results on September 23, 2025, conference call. (Operator Instructions)
Please note this conference is being recorded. I will now turn the conference over to your host, Robert Blum with Lytham Partners. You may begin.
All right, thank you very much, and good afternoon, everyone. As the operator indicated, during today's call we will be discussing Aytu BioPharma's fiscal 2025 full year and fourth quarter operational and financial results. This is for the period ended June 30, 2025.
Joining us on today's call is Aytu's Chief Executive Officer, Josh Disbrow, and Ryan Selhorn, the company's Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session.
I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
